Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving Cervarix or Gardasil Human Papillomavirus Vaccines.

Next Previous
Trial Profile

A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving Cervarix or Gardasil Human Papillomavirus Vaccines.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Jan 2022 Results of an analysis assessing the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection published in the Vaccine
  • 27 Mar 2019 Results evaluating the durability of vaccine and non-vaccine antibody responses of Cervarix or Gardasil vaccine published in the Vaccine
  • 25 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top